Novo Nordisk announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a study involving 254 participants over 26 weeks. This open-label, randomized, controlled, multi-arm trial assessed the…
The anticipated growth of the global PEGylated proteins market is significant, with projections indicating a rise from $10.2 billion in 2023 to $15.9 billion by 2028, reflecting a robust compound…
Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a…
A clinical-stage biopharmaceutical company, specializing in the advancement and market introduction of seralutinib for the management of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD),…
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March…
A leading performance beauty enterprise, specializing in curating an aesthetic range of consumer brands, has announced the allocation of non-qualified stock options for the acquisition of a combined total of…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) disclosed today that its Compensation Committee, a part of Mirum’s Board of Directors, has authorized the allocation of inducement awards to 11 new recruits under…
Today, governments worldwide have reaffirmed their commitment to advancing a proposed pandemic agreement, aiming to refine the draft in preparation for the Seventy-seventh World Health Assembly commencing on May 27,…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) revealed today its plans to showcase pivotal findings from the CAHtalyst™ Adult Phase 3 clinical study, shedding light on baseline characteristics of adults grappling with…
Viatris has just announced its financial outcomes for the initial quarter of 2024, showcasing sustained progress and the robustness of its core operations. Executive Insights Scott A. Smith, CEO of…
Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an…
argenx, a global leader in immunology dedicated to enhancing the lives of individuals grappling with severe autoimmune disorders, has unveiled its financial results for the first quarter of 2024 along…